跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2018-000363-91-DE
EUCTR2018-000363-91-DE进行中（未招募）1 期

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

Calithera Biosciences Inc0 个研究点目标入组 416 人开始时间: 2018年6月28日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
1 期
状态
进行中（未招募）
入组人数
416
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1. Informed Consent
  • •a. Ability to provide written informed consent in accordance with federal, local, and institutional guidelines
  • •2. Target Population
  • •a. Documented histological or cytological diagnosis of renal cell
  • •carcinoma with a clear-cell component
  • •b. Age = 18 years
  • •c. Karnofsky Performance Score (KPS) = 70% (Attachment 4)
  • •d. Estimated Life Expectancy of at least 3 mo
  • •e. Measurable Disease per RECIST 1.1 as determined by the Investigator (see Attachment 5)
  • •f. One and not more than two prior systemic lines of therapy (monotherapy or combination regimen) for advanced or metastatic RCC 1) Must include either:
  • •i. one anti-angiogenic therapy (any VEGF pathway-targeted agent, used either as monotherapy or as a component of a combination regimen)
  • •ii. the combination regimen of nivolumab + ipilimumab
  • •2) Exposure to a prior treatment regimen for =4 weeks is considered a prior line of therapy, regardless of reason for its discontinuation (exception: high-dose IL2 will count as prior therapy if >3 doses administered)
  • •i. 4 weeks will be counted from first to last dose for regimens that are intended to be administered on daily schedules (e.g., sunitinib, pazopanib) and from first dose to end of cycle length after last dose for regimens that are intended to be administered in intervals of = 1 week (e.g., one treatment of a Q2W regimen counts as 2 weeks of therapy)
  • •3) Rechallenge with the same agent or regimen will not be considered a new line of therapy, if the patient had not previously discontinued that agent or regimen because of disease progression
  • •4) Systemic adjuvant therapy is considered a prior line of therapy if the patient has disease recurrence on or within 1 year after the last dose of adjuvant therapy
  • •g. The patient must have had radiographic evidence of disease progression on or after the most recent systemic therapy and within 6 mo before randomization.
  • •3. Laboratory Findings
  • •a. Serum creatinine = 2.0 × upper limit of normal or calculated creatinine clearance (CCr) = 30 mL/min (= 0.5 mL/sec) using the Cockcroft-Gault equation: CCr = {((l40 – age) x actual body weight)/ (72 x SCr)} x 0.85 (if female)
  • •b. Adequate hematological function, defined as absolute neutrophil count = 1,500/mm3, hemoglobin = 9.0 g/dL, and platelet count = 100,000/mm3. Transfusions and growth factors must not be used within 2 weeks prior to randomization to meet these requirements.
  • •c. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3.0 × upper limit of normal.
  • •d. Total bilirubin = 1.5 × the upper limit of normal. For patients with Gilbert’s disease, = 3 mg/dL (= 51.3 µmol/L).
  • •e. Urine protein-to-creatinine ratio (UPCR) = 1 mg/mg (= 113.2 mg/mmol) or 24-hour urine protein < 1 g.
  • •4. Reproductive Status
  • •Female patients of childbearing potential must have a negative serum or urine pregnancy test and if sexually active must agree to contraceptive requirements outlined in Section 10.6.12.2. Male patients who are sexually active with heterosexual partners of childbearing potential must agree to contraceptive requirements and sperm donation restrictions outlined in Section 10.6.12.2.
  • •5. Other Inclusion Criteria
  • •a. Recovery to baseline or = Grade 1 CTCAE v.4.0 from toxicities related to any prior cancer therapy, unless after discussion with medical monitor adverse events (AEs) are deemed clinically non-significant and/or stable on supportive therapy.
  • •Are the trial subjects under 18? no

排除标准

  • •1.Medical History
  • •a.Prior treatment with cabozantinib (or other MET inhibitor) or CB-839
  • •b.Receipt of any anticancer therapy within the following windows before randomization:
  • •Small molecule receptor tyrosine kinase inhibitor (TKI) therapy(including investigational) within 2wks or 5 half-lives, whichever longer
  • •Any type of anticancer antibody/cytotoxic chemotherapy within 4wks
  • •Radiation therapy for bone metastasis within 2wks, any other external radiation therapy within 4wks, systemic treatment with radionuclides within 6wks before randomization. Patients with clinically relevant ongoing complications (per investigator assessment) from prior radiation therapy.
  • •Other investigational therapy within 4wks or 5 half-lives, whichever
  • •c.Patients with active and/or untreated central nervous system (CNS)
  • •cancer are not eligible. Patients with treated brain metastases (1) must have documented radiographic stability of at least 4wks duration demonstrated on baseline contrast-enhanced CNS imaging (e.g., contrast-enhanced MRI of the brain) prior to randomization and (2) must be symptomatically stable and off of steroids (for the purpose of treating symptoms of brain metastases) for at least 2wks before randomization.
  • •d.Any other current or previous malignancy within the past 3yrs except:
  • •Adequately treated basal cell or squamous cell skin cancer,
  • •Carcinoma in situ of the cervix,
  • •Other neoplasm that, in the opinion of the Principal Investigator and with the agreement of the Medical Monitor, will not interfere with study-specific endpoints
  • •e.Previously identified allergy or hypersensitivity to components of the study treatment formulations. (Note: patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take cabozantinib and are also excluded).
  • •f.Corrected QT interval (QTc) > 500 msec within 1mo before
  • •randomization
  • •Cabozantinib should be used with caution in patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with clinically relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances.
  • •2. Concurrent Conditions
  • •a.Unable to receive oral medications or any condition that may prevent adequate absorption of oral study medication including refractory nausea and vomiting, uncontrolled diarrhea, malabsorption, small bowel resection or gastric bypass surgery, use of feeding tubes.
  • •b. Major surgery (e.g., GI surgery) within 6wks before first dose of study treatment or incomplete wound healing from any prior surgery. Patients with clinically relevant ongoing complications (per investigator assessment) from prior surgery are not eligible.
  • •c.The patient has uncontrolled, significant current or recent illness
  • •including, but not limited to, the following conditions:
  • •Cardiovascular disorders:
  • •i.Symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmias
  • •ii.Uncontrolled hypertension defined as sustained BP > 150 mmHg
  • •systolic or > 100 mmHg diastolic despite optimal antihypertensive
  • •iii: Stroke (including TIA), myocardial infarction, or other ischemic event within 6 mo before randomization
  • •GI disorders including those associated with a high risk of perforation or fistula formation:
  • •i.Tumors invading the GI tract, active peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or

研究者

相似试验

进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy
EUCTR2017-001821-42-FRChemoCentryx, Inc.44
进行中（未招募）
1 期
Study of ISIS 304801 versus placebo Administered Subcutaneously to Patients with HypertriglyceridemiaHypertriglyceridemia
EUCTR2014-003434-93-GBIonis Pharmaceuticals, Inc.105
进行中（未招募）
1 期
First-line Esophageal Carcinoma Study with Chemo vs. Chemo + Pembrolizumab
EUCTR2017-000958-19-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.700
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of a group of related conditions that cause the kidneys to malfunction, called C3 Glomerulopathy.
EUCTR2017-001821-42-IEChemoCentryx, Inc.88
进行中（未招募）
1 期
A Clinical Trial to test the effect of Carboplatin and Paclitaxel, with or without Debio 1143 in patients with newly diagnosed Advanced Epithelial Ovarian Cancer.ewly Diagnosed Advanced Epithelial Ovarian CancerMedDRA version: 19.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-005137-42-FRDebiopharm International SA84
A Randomized, Double-Blind, Placebo-Controlled Phase... | 临床试验